Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have nothing good to say about today's NSAV. See you all tomorrow.
No news, no tweets?
38 Mil for Buys and 43 Mil for sells are today results for NSAV. :(
The point is we need some real achievements/results to finish green.
EXACTLY!!!
I believe that staying as we are for now is good and the only reasonable option for RSHN and everyone else involved. Now we/RSHN have only one goal, but the most important one - LETS MAKE MONEY! GLTA.
I'm still buying today. $$$NSAV$$$
Thanks for moving out. :)
How about 1 Sec chart?
And nice gain so far. HALB.
Halberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding Results
Press Release | 08/30/2021
JACKSON CENTER, PA / ACCESSWIRE / August 30, 2021 / Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer's Disease eradication experimentation being conducted at Youngstown State University (YSU) and Arizona State University (ASU). Following standard scientific methodology, Halberd conducted two rounds of experimentation on Phosphorylated Tau, and the results were so astounding that the researchers want to conduct further replication tests prior to publication in scientific articles.
Bodily fluids treated with nanoparticles conjoined to specific antibodies attract and adhere to target disease antigens. These conjoined target antigens are subjected to laser emissive energy and to radio frequency waves in separate experiments. Halberd's initial target disease antigen, Phosphorylated Tau, is the primary building block of neurofibrillary tangles associated with the onset and progression of Alzheimer's Disease and other neurodegenerative diseases.
William A. Hartman, Halberd Corporation's Chairman, President & CEO, stated. "Once the replication testing is completed, our researchers will commence writing scientific articles on the technology and results. These tests and the scientific documents should be completed within the next several weeks. Testing on the other antigens associated with Alzheimer's Disease will commence at that time."
"Halberd's previous testing on E. Coli also yielded stunningly positive results, which are also being replicated prior to publication," Hartman concluded.
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies.
Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome.
https://www.otcmarkets.com/stock/HALB/news/Halberd-Corporation-Alzheimers-Disease-Treatment-Tests-Yield-Outstanding-Results?id=318535
Then it was my misunderstanding. SORRY>
With 6 B AS how did you get to 24 B MC @ 1 $ PPS?
I bring my STEEL PRICE UP to 8 C! No charts, just my feelings. GLTY! You all deserve it!!! $$$NSAV$$$
As I posted before $$$NSAV$$$ under 5C is a steel. I did today. GLTA>
They shouldn't, I'm still buying. Under 8 is a privilege, under 5 is a steel. $$$NSAV$$$
Big and good news for RSHN and shareholders.
It's going to work @ .25C and higher. Just one down day for $$$NSAV$$$.
Chartmaster, may I ask you where do you have NSAV to be by the end of this year if NSAV will be able to achieve all their this year's goals? Also, what is the reasonable NSAV price till it settles to normal trading range? Thank you.
SOLD ALL I HAD LEFT. MADE MONEY IN KGKG> THANK YOU ALL FOR THE COMPANY> GLTA.
Rounded UP my numbers.
Sold the last ones, being in IDGC for ages, but made good money. GLTA.
And still buying.
Still just the beginning for $$$NSAV$$$. Under 8 C not for long.
$$$NSAV$$$ should be @ 8 C now. GLTA.
HeliosDX's revenues increased in the past few months - averaging $600,000 per month. HeliosDX combined with Grandeza Healthcare brings RushNet's annual revenue to a run rate exceeding $7,600,000. Ashley Sweat, CEO of RushNet, Inc. and heliosDX says, "both of these acquisitions are strategic and paramount to the future of RushNet and its future. To have these acquisitions closed in such a timely manner is a testament to the internal team, accountants, attorneys, and other many individuals who worked tirelessly to get the job done and to bring value to each and to thus enable RushNet to continue its course of accretive acquisitions.
NSAV under 8 C is a steel IMO.
Buys 2x over sells. $$$NSAV$$$.
Great news, excellent post!
Halberd Files Provisional Patent Application - Furthering Efforts on Alzheimer's Disease
Mon, August 23, 2021, 5:00 AM
JACKSON CENTER, PA / ACCESSWIRE / August 23, 2021 / Halberd Corp. (OTC PINK:HALB) announced filing a U. S. joint provisional patent application, "Treating Alzheimer's Disease Utilizing Extracorporeal Radio Frequency." The innovation is a result of Halberd's Sponsored Research conducted at Arizona State University (ASU) and Youngstown State University (YSU). The provisional patent application covers technology developed to treat blood or cerebral spinal fluid extracorporeally through exposure to, and elimination via, radio frequency (RF) waves or laser emissive energy.
Dr. Mitchell S. Felder, Halberd Corporation's Chief Technical Officer and co-inventor of the technology, stated, "The conjugation of a metallic nanoparticle with an antibody targets specific Alzheimer's Disease-related antigens. The conjugated antibody/particles bind to the target antigens within the bodily fluid. The treated bodily fluid is then exposed to tuned radio frequency waves or laser energy which causes the conjoined metallic nanoparticles to heat up, thereby destroying the target antigens. Elimination of the target antigens slows or arrests the progression of the disease. We are excited by the very promising results of our testing of this technology to date at YSU and ASU."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Halberd's patented extracorporeal treatment process permits us, exclusively, to target and treat specific diseases outside of the body. This approach reduces or eliminates any potential dangerous side-effects from standard treatments, such as drugs introduced into the body administered orally, or injected. This latest filing is Halberd's tenth provisional patent application submitted in a little over a year. Each such patent evidences the incremental success of Halberd's unique and exclusive strategy. Halberd's testing of the process to eradicate Alzheimer's Disease antigens through RF and/or laser exposure, continues in conjunction with YSU. ASU then verifies YSU's eradication in test samples. We have experienced encouraging results to date in successfully eradicating select Alzheimer's Disease antigens and continue to fine tune the process before moving on to other target antigens."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:
Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/660857/Halberd-Files-Provisional-Patent-Application--Furthering-Efforts-on-Alzheimers-Disease
I'm with you on RSHN for Monday.
Done.
We are not talking about overnight here. We are talking about incredible team here for a while. I'm not going any there or sell any of my shares. May be I was too optimistic, but I'm giving them a benefit of the doubt now. GLTA.
The new management still has to proof itself to shareholders. I see no noticeable achievements yet. GLTA.
NSAV is not looking as good as it should be at this point. FACT> :(
Here is my opinion : we have an ambitious and knowledgeable CEO! $$$NSAV$$$
And this is how I like you!!!
Ugly and disappointing week is OVER! Still holding all of mine. GLTA.
And BIG time.
What a day :(((.